PUBLISHER: The Business Research Company | PRODUCT CODE: 2082235
PUBLISHER: The Business Research Company | PRODUCT CODE: 2082235
Point-of-care immunoassay analyzer expansion refers to the advancement, manufacturing, and adoption of point-of-care immunoassay analyzers for rapid diagnostic testing near the patient. These analyzers utilize immunoassay methods to identify specific proteins, hormones, antigens, or antibodies in biological samples such as blood, urine, or saliva, delivering quick and reliable results to support clinical decision-making.
The primary product types of point of care immunoassay analyzer expansion include portable analyzers, benchtop analyzers, and microfluidic analyzers. Portable analyzers refer to compact diagnostic devices developed for rapid immunoassay testing at or near the patient location, supporting quick clinical decision-making. These solutions are based on technologies such as chemiluminescence, enzyme-linked immunosorbent assay, and lateral flow assay and they utilize sample types including blood, urine, and saliva. The applications involved are infectious diseases, hormonal testing, autoimmune disorders, cardiac markers, and oncology, while the end-use includes hospitals, diagnostic laboratories, home care settings, and academic research institutions.
Tariffs are influencing the point-of-care (poc) immunoassay analyzer expansion market by increasing the cost of imported diagnostic instruments, reagents, microfluidic cartridges, and semiconductor-based components essential for analyzer production. This is slowing the deployment of portable, benchtop, and microfluidic systems, particularly in import-dependent regions such as Asia-Pacific and Latin America, where healthcare infrastructure expansion depends heavily on international suppliers. Hardware-intensive segments such as fully automated benchtop analyzers and cartridge-based microfluidic systems are most impacted due to complex cross-border supply chains. However, tariffs are also driving localization of manufacturing, strengthening regional supply ecosystems, and encouraging domestic production of diagnostic equipment, ultimately improving long-term supply chain resilience and market stability.
The point of care (POC) immunoassay analyzer expansion market research report is one of a series of new reports from The Business Research Company that provides point of care (POC) immunoassay analyzer expansion market statistics, including point of care (POC) immunoassay analyzer expansion industry global market size, regional shares, competitors with a point of care (POC) immunoassay analyzer expansion market share, detailed point of care (POC) immunoassay analyzer expansion market segments, market trends and opportunities, and any further data you may need to thrive in the point of care (POC) immunoassay analyzer expansion industry. This point of care (POC) immunoassay analyzer expansion market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The point of care (POC) immunoassay analyzer expansion market size has grown strongly in recent years. It will grow from $4.9 billion in 2025 to $5.31 billion in 2026 at a compound annual growth rate (CAGR) of 8.6%. The growth in the historic period can be attributed to rising prevalence of infectious diseases, growth of hospital laboratory infrastructure, increasing demand for rapid diagnostics, expansion of immunoassay technology adoption, improvements in antibody and antigen detection methods.
The point of care (POC) immunoassay analyzer expansion market size is expected to see strong growth in the next few years. It will grow to $7.45 billion by 2030 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to expansion of personalized medicine and biomarker-based testing, increasing shift toward decentralized healthcare delivery, rising adoption of ai-enabled diagnostic systems, growth in home-based healthcare monitoring, increasing regulatory approvals for rapid diagnostic devices. Major trends in the forecast period include expansion of decentralized point-of-care diagnostic ecosystems, increasing adoption of multiplex immunoassay platforms, integration of wireless connectivity in portable analyzers, growth of cartridge-based rapid testing systems, rising demand for at-home immunodiagnostic solutions.
The increasing prevalence of infectious diseases is expected to propel the growth of the point of care immunoassay analyzer expansion market going forward. Infectious diseases are medical conditions caused by pathogenic microorganisms such as bacteria, viruses, parasites, or fungi that spread directly or indirectly between individuals. The increasing prevalence of infectious diseases is driven by rising global population density, which accelerates transmission risks and the spread of diseases. Point of care (POC) immunoassay analyzer expansion supports the management of infectious diseases by enabling rapid, accurate, and decentralized detection of infectious biomarkers, thereby strengthening early diagnosis and disease control efforts. For instance, in March 2025, according to the UK Health Security Agency, a UK-based government health authority, tuberculosis cases in England increased by 13% in 2024, reaching 5,480 cases compared to 4,850 cases in 2023. Therefore, the increasing prevalence of infectious diseases is driving the growth of the point of care immunoassay analyzer expansion market.
Leading companies operating in the point of care immunoassay analyser expansion market are concentrating on developing innovative solutions, such as advancements in immunoassay technologies, to address the growing demand for rapid diagnostics, decentralized healthcare, and real-time clinical decision-making in emergency and remote settings. These advanced immunoassay analyzers are compact diagnostic platforms that use antigen-antibody reactions to detect biomarkers with high sensitivity, offering capabilities such as rapid turnaround times, portability, minimal sample preparation, and multiplex testing functions; unlike conventional centralized laboratory analyzers that require sophisticated infrastructure and longer processing durations, POC systems facilitate near-patient testing with faster results and greater accessibility. For instance, in July 2023, Anbio Biotechnology launched the AF-100S Fluorescence Immunoassay Analyzer. This system is a compact, automated fluorescent immunoassay analyzer developed for rapid quantitative detection of biomarkers in clinical samples such as whole blood, serum, and plasma. It combines fluorescence-based detection technology with automated calibration and integrated quality control to ensure high sensitivity and accuracy comparable to centralized laboratory systems. Additionally, the analyzer includes a user-friendly interface and delivers test results within minutes, making it highly suitable for emergency departments, clinics, and decentralized healthcare environments.
In August 2024, Roche acquired LumiraDx point-of-care technology assets for an undisclosed amount. Through this acquisition, Roche aims to strengthen its diagnostics portfolio by integrating LumiraDx's innovative point-of-care testing platform, which includes immunoassay-based diagnostic capabilities, and expanding its presence in decentralized healthcare solutions. LumiraDx is a UK-based diagnostics company specializing in rapid point-of-care testing technologies.
Major companies operating in the point of care (poc) immunoassay analyzer expansion market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Abbott Laboratories, Siemens Healthineers AG, Danaher Corporation, Becton, Dickinson and Company (BD), Beckman Coulter, Bruker Corporation, BioRad Laboratories, Qiagen N. V., Diasorin, Lepu Medical Technology, SD Biosensor, Eiken Chemical Co. Ltd., Molbio Diagnostics Pvt. Ltd., Maccura Biotechnology Co. Ltd., QuantuMDx Group Ltd., Ustar Biotechnologies Ltd., Mylab Discovery Solutions Pvt Ltd., Akonni Biosystems Inc., Zeesan Biotech Co. Ltd.
North America was the largest region in the point-of-care immunoassay analyzer expansion market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the point of care (POC) immunoassay analyzer expansion market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the point of care (POC) immunoassay analyzer expansion market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The point-of-care immunoassay analyzer expansion market consists of revenues earned by entities by providing services such as analyzer installation, calibration, maintenance, cloud-based data connectivity, software integration, remote monitoring, and consumable supply services. The market value also includes the value of related goods sold by the service provider or included within the service offering. The point-of-care immunoassay analyzer expansion market also includes sales of POC immunoassay analyzers, peripheral devices, biosensors, handheld analyzers, automated test systems, sample preparation devices, and associated accessories. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream healthcare providers, distributors, or retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Point Of Care (POC) Immunoassay Analyzer Expansion Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses point of care (poc) immunoassay analyzer expansion market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for point of care (poc) immunoassay analyzer expansion ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The point of care (poc) immunoassay analyzer expansion market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.